Literature DB >> 28766045

PAD2 overexpression in transgenic mice augments malignancy and tumor-associated inflammation in chemically initiated skin tumors.

Sunish Mohanan1, Sachi Horibata1,2, Lynne J Anguish1, Chinatsu Mukai1, Kelly Sams1, John L McElwee1, Dalton McLean1, Angela Yan1, Scott A Coonrod3,4.   

Abstract

We previously found that transgenic mice overexpressing MMTV-FLAG-hPAD2 (PAD2OE) developed spontaneous skin lesions, with a subset of these lesions progressing to invasive squamous cell carcinoma (SCC). The goal of this report was to better understand the potential mechanisms by which PAD2 overexpression promotes skin cancer. Here, PAD2OE mice were treated with the carcinogen, 9,10-dimethyl-1,2-benzanthracene and with O-tetradecanoylphorbol-13-acetate and then scored for papilloma formation. Additionally, tumor sections were evaluated for evidence of tumor cell invasion and inflammation. We found that the total number of papillomas was significantly increased in PAD2OE mice compared to controls. Histopathologic analysis of the lesions found that in PAD2OE skin tumors progressed to invasive SCC more frequently than controls. Additionally, we found that PAD2OE lesions were highly inflamed, with a dense inflammatory cell infiltrate and an associated increase in nuclear phospho-STAT3 (signal transducer and activator of transcription 3) in the transgenic tumors. These data suggest that overexpression of the hPAD2 transgene in the epidermis increases the malignant conversion rate of benign tumors by promoting an inflammatory microenvironment.

Entities:  

Keywords:  DMBA-TPA carcinogenesis model; PAD2 overexpression; Peptidylarginine deiminase 2 (PAD2); Squamous cell carcinoma; Tumor associated inflammation

Mesh:

Substances:

Year:  2017        PMID: 28766045     DOI: 10.1007/s00441-017-2669-x

Source DB:  PubMed          Journal:  Cell Tissue Res        ISSN: 0302-766X            Impact factor:   5.249


  4 in total

Review 1.  Peptidylarginine Deiminase 2 in Host Immunity: Current Insights and Perspectives.

Authors:  Zhenyu Wu; Patrick Li; Yuzi Tian; Wenlu Ouyang; Jessie Wai-Yan Ho; Hasan B Alam; Yongqing Li
Journal:  Front Immunol       Date:  2021-11-04       Impact factor: 7.561

Review 2.  Peptidyl Arginine Deiminase 2 (PADI2)-Mediated Arginine Citrullination Modulates Transcription in Cancer.

Authors:  Miguel Beato; Priyanka Sharma
Journal:  Int J Mol Sci       Date:  2020-02-17       Impact factor: 6.208

3.  In vivo expression of peptidylarginine deiminase in Drosophila melanogaster.

Authors:  Olena Mahneva; Monica G Risley; Ciny John; Sarah L Milton; Ken Dawson-Scully; William W Ja
Journal:  PLoS One       Date:  2020-01-15       Impact factor: 3.240

4.  Down-regulation of PADI2 prevents proliferation and epithelial-mesenchymal transition in ovarian cancer through inhibiting JAK2/STAT3 pathway in vitro and in vivo, alone or in combination with Olaparib.

Authors:  Lidong Liu; Zhiwei Zhang; Guoxiang Zhang; Ting Wang; Yingchun Ma; Wei Guo
Journal:  J Transl Med       Date:  2020-09-20       Impact factor: 5.531

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.